<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03171818</url>
  </required_header>
  <id_info>
    <org_study_id>NL53975.041.16</org_study_id>
    <nct_id>NCT03171818</nct_id>
  </id_info>
  <brief_title>Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration</brief_title>
  <acronym>DINOSAUR</acronym>
  <official_title>Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alberta Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to perform a randomized double-blind placebo controlled prospective
      study in newborn infants with MRI confirmed Middle Cerebral Artery (MCA) Perinatal Arterial
      Ischemic Stroke (PAIS) with darbepoetin. It will be investigated whether intravenous
      administered darbepoetin can induce the formation of neuronal tissue and restore brain
      function in neonates who suffered from PAIS compared to placebo treated controls. The
      ultimate goal of this study is therefore to develop a therapy using
      erythropoiesis-stimulating agents (ESA) such as darbepoetin to reduce or even prevent
      lifelong consequences of PAIS-related brain injury in this group of term newborns.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An international multicenter, randomized placebo controlled intervention study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This will be a double-blinded study, meaning that both the patient (and his/her parents) and the health care providers, including neonatologist, pediatrician, nurses, physiotherapists, etc, are not allowed to know what treatment the patient has been given. Those that collect outcome parameters, such as MRI data and neurodevelopmental outcome, are also unaware of treatment allocation, meaning that blinding will be maintained during the full study-period of 18 months.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in stroke tissue loss</measure>
    <time_frame>6-8 weeks of age</time_frame>
    <description>The primary objective is to determine whether there is a difference in the degree in stroke tissue loss between darbepoetin and placebo treatment, which will be measured by the change in lesion size between the time of onset of the insult and 6-8 weeks of age. The primary endpoint will be estimated using advanced volumetric magnetic resonance (MRI) techniques, performed within one week after clinical presentation and at 6-8 weeks of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reorganization of corticospinal connectivity</measure>
    <time_frame>6-8 weeks of age</time_frame>
    <description>To assess whether there are differences between darbepoetin and placebo treatment in Diffusion Tensor Imaging (DTI) parameters of selected regions of interest. DTI-MRI techniques are performed at 6-8 weeks of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment</measure>
    <time_frame>18 months of age</time_frame>
    <description>To assess cognitive and motor development at 18 months of age using the Bayley Scales of Infants and Toddler Development (BSITD)-III scores compare them between groups (darbepoetin vs placebo).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological assessment</measure>
    <time_frame>18 months of age</time_frame>
    <description>To assess neurological deficit and function using the Pediatric Stroke Outcome Measure (PSOM) and compare this score between groups (darbepoetin vs placebo). The PSOM is performed at 18 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Cerebral Palsy</measure>
    <time_frame>18 months of age</time_frame>
    <description>Development of Unilateral Spastic Cerebral Palsy (USCP) using the Gross Motor Function Classification system (GMFCS) and compare this between groups (darbepoetin vs placebo).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>PAIS</condition>
  <condition>Neonatal Stroke</condition>
  <condition>Perinatal Stroke</condition>
  <arm_group>
    <arm_group_label>Darbepoetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darbepoetin alfa (Aranesp, Amgen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin Alfa</intervention_name>
    <description>Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.</description>
    <arm_group_label>Darbepoetin</arm_group_label>
    <other_name>Aranesp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborns â‰¥ 36+0 weeks of gestation, both male and female

          -  MRI confirmed diagnosis of acute PAIS, in the MCA region with involvement of the
             cortical spinal tract (e.g. Posterior Limb of Internal Capsule [PLIC] or peduncles)
             within one week after birth

          -  Written informed consent from custodial parent(s)

        Exclusion Criteria:

          -  Moderate -severe Hypoxic-Ischemic Encephalopathy (HIE) with or without hypothermia
             therapy

          -  Any proven or suspected major congenital anomaly, chromosomal disorder, metabolic
             disorder;

          -  Presence of a serious infection of the central nervous system;

          -  No realistic prospect of survival, (e.g. severe brain injury), at the discretion of
             the attending physician.

          -  Infant for whom withdrawal of supportive care is being considered.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manon Benders, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manon Benders, MD PhD</last_name>
    <phone>+31 88 755 5555</phone>
    <email>m.benders@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nienke Wagenaar, MD</last_name>
    <phone>+31 88 755 5555</phone>
    <email>n.wagenaar@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wilhelmina Childrens Hostpital/University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manon Benders, MD, PhD</last_name>
      <phone>+31(0)887554545</phone>
    </contact>
    <contact_backup>
      <last_name>Nienke Wagenaar, MD</last_name>
      <phone>+31(0)887554545</phone>
      <phone_ext>63630</phone_ext>
      <email>n.wagenaar@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Linda S de Vries, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manon JN Benders, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nienke Wagenaar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Floris Groenendaal, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeroen Dudink, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Benders MJ, van der Aa NE, Roks M, van Straaten HL, Isgum I, Viergever MA, Groenendaal F, de Vries LS, van Bel F. Feasibility and safety of erythropoietin for neuroprotection after perinatal arterial ischemic stroke. J Pediatr. 2014 Mar;164(3):481-6.e1-2. doi: 10.1016/j.jpeds.2013.10.084. Epub 2013 Dec 8.</citation>
    <PMID>24321539</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Linda de Vries, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator UMC Utrecht</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

